• Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials …
Press Release
Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference
NEW YORK and LONDON, October 31, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
NEW YORK and LONDON, October 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing …
Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
NEW YORK and LONDON, September 22, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
